Background: Severe acute colitis is a common complication of inflammatory bowel disease (IBD). Their diagnosis is based on clinical, laboratory, endoscopic and radiological. The severe acute colitis is a medical and surgical emergency; its mortality is 1% to 3%. The management should be swift and coordinated, upon admission, between medical and surgical teams. Methods: This is a retrospective study in Gastroenterology Service at the University Hospital HASSAN II Fez, over a period of 10 years (2005-2015). We included all patients admitted for severe acute colitis; all the epidemiological, clinical, endoscopic, histological, and therapeutic monitoring of patients were collected. Results: We collected 123 patients. Their average age was 35 years (16 - 70). It was a female predominance (sex ratio F/M = 1.19). 54 patients were admitted for an inaugural severe acute colitis (43%), while 69 patients were known carriers of IBD (56%). All patients were admitted to an array of severe acute colitis according to the criteria of Truelove and Witts modified. 9 patients were operated urgently because there was the presence of complications (5 cases of perforation, 3 cases of massive rectal bleeding, and one patient with an abscess in the right iliac fossa). Corticosteroids intravenously was administered to 114 patients, 74 patients (64%) had remission. Patients who have not responded to corticosteroids IV (N = 40): 1) 12 patients received treatment with oral cyclosporine: the remission rate was 66%. 2) 8 patients were put under Infliximab: The response rate was 75%. 3) Patients who have not responded to a second-line treatment underwent subtotal colectomy with a dual stoma. 4) The surgery was indicated as a second-line treatment in 20 patients who all received a subtotal colectomy with double stoma; totalizing colectomy and ileoanale anastomosis ware made in 4 patients. The mortality rate is higher in our series (12%) mainly postoperatively; it is due to the delayed admission of patients, which promotes the development of complications. Conclusion: Acute Severe Ulcerative Colitis is a medical and surgical emergency that requires a multidisciplinary approach; medical treatment is the basis of initial treatment; but surgery must always be indicated at the right time avoiding increasing the death rate, this rate is important in our series.
References
[1]
Jewell, D., et al. (1991) Indications and Timing of Surgery for Severe Ulcerative Colitis. Gastroenterology International, 4, 161-164.
[2]
Dignass, A., Lindsay, J., Sturm, A., et al. (2012) Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn’s and Colitis, 6, 991-1030.
https://doi.org/10.1016/j.crohns.2012.09.002
[3]
Turner, D., Walsh, C.M., Steinhart, A.H. and Griffiths, A.M. (2007) Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and Meta-Regression. Clinical Gastroenterology and Hepatology, 5, 103-110.
https://doi.org/10.1016/j.cgh.2006.09.033
[4]
Travis, S.P., Farrant, J.M., Ricketts, C., et al. (1996) Predicting Outcome in Severe Ulcerative Colitis. Gut, 38, 905-910. https://doi.org/10.1136/gut.38.6.905
[5]
Carbonnel, F., Gargouri, D., Lémann, M., et al. (2000) Predictive Factors of Outcome of Intensive Intravenous Treatment for Attacks of Ulcerative Colitis. Alimentary Pharmacology and Therapeutics, 14, 273-279.
https://doi.org/10.1046/j.1365-2036.2000.00705.x
[6]
Benazzato, L., D’Inca, R., Grigoletto, F., et al. (2004) Prognosis of Severe Attacks in Ulcerative Colitis: Effect of Intensive Medical Treatment. Digestive and Liver Disease, 36, 461-466. https://doi.org/10.1016/j.dld.2003.12.017
[7]
Daperno, M., Sostegni, R., Scaglione, N., et al. (2004) Outcome of a Conservative Approach in Severe Ulcerative Colitis. Digestive and Liver Disease, 36, 21-28.
https://doi.org/10.1016/j.dld.2003.04.001
[8]
Manosa, M., Cabré, E., Garcia-Planella, E., et al. (2011) Decision Tree for Early Introduction of Rescue Therapy in Active Ulcerative Colitis Treated with Steroids. Inflammatory Bowel Diseases, 17, 2497-2502. https://doi.org/10.1002/ibd.21634
[9]
Gan, S.I. and Beck, P.L. (2003) A New Look at Toxic Megacolon: An Update and Review of Incidence, Etiology, Pathogenesis, and Management. American Journal of Gastroenterology, 98, 2363-2371. https://doi.org/10.1111/j.1572-0241.2003.07696.x
[10]
Dinesen, L.C., Walsh, A.J., Protic, M.N., et al. (2010) The Pattern and Outcome of Acute Severe Colitis. Journal of Crohn’s and Colitis, 4, 431-437.
https://doi.org/10.1016/j.crohns.2010.02.001
[11]
Hoie, O., Wolters, F., Riss, L., Bernklev, T., Aamodt, G., Clofent, J., et al. (2007) Low Colectomy Rates in Ulcerative Colitis in an Unselected European Cohort Followed for 10 Years. Gastroenterology, 132, 507-515.
https://doi.org/10.1053/j.gastro.2006.11.015
[12]
Kaplan, G.G., McCarthy, E.P., Ayanian, J.Z., Korzenik, J., Hodin, R. and Sands, B.E. (2008) Impact of Hospital Volume on Postoperative Morbidity and Mortality Following a Colectomy for Ulcerative Colitis. Gastroenterology, 134, 680-687.
https://doi.org/10.1053/j.gastro.2008.01.004
[13]
Saha, S.K., Kumar, A., Panwar, R., et al. (2015) Early Colectomy in Steroid-Refractory Acute Severe Ulcerative Colitis Improves Operative Outcome. Apollo Medicine, 12, S25. https://doi.org/10.1016/j.apme.2015.11.073
[14]
Seo, H.I., Park, D.I., Kim, T.O., et al. (2014) The Effect of Infliximab on Patients with Ulcerative Colitis in Korea. Intestinal Research, 12, 214-220.
https://doi.org/10.5217/ir.2014.12.3.214
[15]
Gisbert, J.P., Gonzalez-Lama, Y. and Mate, J. (2007) Systematic Review: Infliximab Therapy in Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 25, 19-37.
https://doi.org/10.1111/j.1365-2036.2006.03131.x
[16]
Arias, M.T., Casteele, N.V., Vermeire, S., et al. (2015) A Panel to Predict Long-Term Outcome of Infliximab Therapy for Patients with Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 13, 531-538.
https://doi.org/10.1016/j.cgh.2014.07.055
[17]
Monterubbianesi, R., Aratari, A., Armuzzi, A., et al. (2014) Infliximab Three-Dose Induction Regimen in Severe Corticosteroid-Refractory Ulcerative Colitis: Early and Late Outcome and Predictors of Colectomy. Journal of Crohn’s and Colitis, 8, 852-858. https://doi.org/10.1016/j.crohns.2014.01.006
[18]
Creed, T.J. and Probert, C.S. (2007) Review Article: Steroid Resistance in Inflammatory Bowel Disease—Mechanisms and Therapeutic Strategies. Alimentary Pharmacology & Therapeutics, 25, 111-122.
https://doi.org/10.1111/j.1365-2036.2006.03156.x
[19]
de Saussure, P., Soravia, C., Morel, P. and Hadengue, A. (2005) Low-Dose Oral Microemulsion Ciclosporin for Severe, Refractory Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 22, 203-208.
https://doi.org/10.1111/j.1365-2036.2005.02552.x
[20]
Weber, A., Fein, F., Koch, S., Dupont-Gossart, A.C., Mantion, G., Heyd, B., et al. (2006) Treatment of Ulcerative Colitis Refractory to Steroid Therapy by Microemulsion Cyclosporine (Neoral). Inflammatory Bowel Diseases, 12, 1131-1135.
https://doi.org/10.1097/01.mib.0000235096.78736.8e
[21]
Chang, K.H., Burke, J.P. and Coffey, J.C. (2013) Infliximab versus Cyclosporine as Rescue Therapy in Acute Severe Steroid-Refractory Ulcerative Colitis: A Systematic Review and Meta-Analysis. International Journal of Colorectal Disease, 28, 287-293. https://doi.org/10.1007/s00384-012-1602-8
[22]
Laharie, D., Bourreille, A., Branche, J., et al. (2012) Ciclosporin versus Infliximab in Patients with Severe Ulcerative Colitis Refractory to Intravenous Steroids: A Parallel, Open-Label Randomised Controlled Trial. The Lancet, 380, 1909-1915.
https://doi.org/10.1016/S0140-6736(12)61084-8
[23]
Sjöberg, M., Walch, A., Meshkat, M., et al. (2012) Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study. Inflammatory Bowel Diseases, 18, 212-218.
https://doi.org/10.1002/ibd.21680
[24]
Croft, A., Walsh, A., Doecke, J., Cooley, R., Howlett, M. and Radford-Smith, G. (2013) Outcomes of Salvage Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis: Ciclosporin vs. Infliximab. Alimentary Pharmacology & Therapeutics, 38, 294-302. https://doi.org/10.1111/apt.12375
[25]
Kim, E.H., Kim, D.H., Park, S.J., et al. (2015) Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study. Gut and Liver, 9, 601-606.
https://doi.org/10.5009/gnl14120
[26]
Llaó, J., Naves, J.E., Ruiz-Cerulla, A., et al. (2016) Improved Outcome of Acute Severe Ulcerative Colitis While Using Early Predictors of Corticosteroid Failure and Rescue Therapies. Digestive and Liver Disease, 48, 608-612.
https://doi.org/10.1016/j.dld.2016.02.024
[27]
Clementa, V., Aratari, A., Papi, C. and Vernia, P. (2016) Short Term Colectomy Rate and Mortality for Severe Ulcerative Colitis in the Last 40 Years. Has Something Changed? Digestive and Liver Disease, 48, 371-375.
https://doi.org/10.1016/j.dld.2015.12.014
[28]
Alves, A. (2003) Traitement d’une colite aiguë grave compliquant une maladie inflammatoire chronique de l’intestin. American College of Surgeons, 197, 3-9.
